Other News

Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare genetic diseases, today announced the approval of Evkeeza® (evinacumab) in Canada. Evkeeza® was approved by Health Canada as an adjunct to diet and other […]

iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor

SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the U.S. launch of its next-generation Zio® monitor and enhanced Zio® long-term continuous monitoring (LTCM) service. Zio monitor is iRhythm’s smallest, lightest and thinnest cardiac monitor, enhancing the cardiac monitoring experience for patients and healthcare providers together with new service […]

CereVasc eShunt® System Study Data Presented at Congress of Neurological Surgeons Meeting

BOSTON, Sept. 26, 2023 /PRNewswire/ — CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced that data from clinical studies examining the use of its eShunt System to treat elderly patients with normal pressure hydrocephalus and patients with communicating hydrocephalus following treatment for a ruptured cerebral aneurysm, was […]

QT Medical® Announces Completion of Series B Financing of $12 Million

LOS ANGELES, Sept. 26, 2023 /PRNewswire/ — QT Medical, Inc., a medtech company focused on cardiac care technology, announced today that it raised $12 million in Series B financing. This funding will accelerate QT Medical’s market penetration, global expansion, product pipeline development, and long-term strategic planning. QT Medical’s PCA 500 is the world’s most compact […]

Acesion Pharma Closes Oversubscribed €45M Series B Financing Round to Advance Development of Novel Therapy for Atrial Fibrillation

COPENHAGEN, Denmark, Sept. 26, 2023 /PRNewswire/ — Acesion Pharma (‘Acesion‘ or ‘the Company‘), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (‘AF‘), the most common cardiac arrhythmia, today announces that it has successfully closed an oversubscribed €45M Series B financing round. The equity financing was co-led by new US-based investors Canaan and Alpha […]

Cardiosense Begins Enrollment in Nationwide Heart Failure Study

CHICAGO, Sept. 26, 2023 /PRNewswire/ — Cardiosense, a digital health company developing a non-invasive monitoring platform for the early detection of heart disease, recently started enrolling patients in SEISMIC-HF I, its nationwide clinical study to refine and validate algorithms to assess intracardiac filling pressure, an early physiological marker for acute heart failure […]

Viz.ai Announces Expansion into Outpatient Ambulatory Centers to Accelerate Clinical Trial Recruitment in Heart Failure

SAN FRANCISCO, CA – September 26, 2023 – Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the expansion into outpatient ambulatory centers to accelerate clinical trial recruitment. Amavita Heart and Vascular Health™, with facilities spanning four locations in Miami-Dade County, has taken a pioneering step by […]

CARMAT Reports Its 2023 Half-Year Results and Provides an Update on Its Strategic Progress

ARIS–(BUSINESS WIRE)–Regulatory News: “During the first half of 2023, the production ramp-up we were anticipating was significantly disrupted by supply issues. Due to the lack of a sufficient number of devices, we were late in generating the demand from hospitals, hence limited revenues in the first half of the year. […]

Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence

Bagsværd, Denmark and Boston, Massachusetts, US, 25 September 2023 – Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases based on Valo’s large human dataset and computation powered by artificial intelligence (AI). The collaboration between the two organizations will leverage the capabilities […]

Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that tegoprubart, the company’s investigational anti-CD40 antibody, was used as a cornerstone component of the chronic immunosuppressive regimen administered following the second-ever transplant of a genetically modified heart from a pig to a human. The procedure […]